Myth: All surfactants are alike

Seminars in Fetal and Neonatal Medicine

Volumn 16, Issue 5, 2011, Pages 269-274

  Moya, Fernando ^a   Javier, Maria Cristina ^a  

^a Neonatal Intensive Care Unit   (United States)

Author keywords

Bronchopulmonary dysplasia; Respiratory distress syndrome; Surfactant

Indexed keywords

BERACTANT; CAFFEINE; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; LUNG SURFACTANT; PHOSPHOLIPID; PORACTANT; PUMACTANT; RETINOL; STEROID; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C;

ABSENCE OF SIDE EFFECTS; ARTIFICIAL VENTILATION; CHEMICAL COMPOSITION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; GASTROESOPHAGEAL REFLUX; HUMAN; IN VITRO STUDY; LUNG ALVEOLUS SURFACE TENSION; LUNG DYSPLASIA; LUNG FUNCTION; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; OXYGEN SATURATION; OXYGEN THERAPY; PNEUMOTHORAX; POSITIVE END EXPIRATORY PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS SYNDROME; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEANING;

BRONCHOPULMONARY DYSPLASIA; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; TREATMENT OUTCOME;

EID: 79960973987     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2011.03.006     Document Type: Review

References (49)

1. Jobe A.H. Pharmacology review: why surfactant works for respiratory distress syndrome. NeoReviews 2006, 7:e95-e106.
2. Soll R. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 1998, (3):CD001149.
3. Seger N., Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009, (2):CD007836.
4. Soll R., Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001, (2):CD000144.
5. Moya F., Maturana A. Animal-derived surfactants versus past and current synthetic surfactants: current status. Clin Perinatol 2007, 34:145-177.
6. Holm B., Cummings J.J. Is there evidence for a mortality difference between exogenous surfactant preparations in neonatal RDS?. J Appl Res 2008, 8:78-83.
7. Perez-Gil J., Keough K.M. Interfacial properties of surfactant proteins. Biochim Biophys Acta 1998, 1408:203-217.
8. Blanco O., Perez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient pulmonary surfactant. Eur J Pharmacol 2007, 568:1-15.
9. Pérez-Gil J., Tucker J., Simatos G., Keough K.M. Interfacial adsorption of simple lipid mixtures combined with hydrophobic surfactant protein from pig lung. Biochem Cell Biol 1992, 70:332-338.
10. Rudiger M., Tolle A., Meier W., Rustow B. Effect of minor components of alveolar surfactant lipids on surface properties. Recent research developments in chemistry and physics of lipids 2003, 1-14. Transworld Research Network, Trivandrum, India.
11. Hall S.B., Venkitaraman A.R., Whitsett J.A. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis 1992, 145:24-30.
12. Cochrane C.G., Revak S.D. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991, 254:566-568.
13. Kinniry P., Pick J., Stephens S., et al. KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice. Pediatr Pulmonol 2006, 41:916-928.
14. Spragg R.G., Lewis J.L., Wurst W., et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Resp Crit Care Med 2003, 167:15-66.
15. Moya F., Hoffman D., Zhao B., Johnston J.M. Platelet activating factor in surfactant preparations. Lancet 1993, 341:858-860.
16. Rudiger M., Tolle A., Meier W., Rustow B. Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am J Physiol Lung Cell Mol Physiol 2005, 288:L379-L383.
17. Kaiser J.R., Gauss C.H., Williams D.K. Surfactant administration acutely affects cerebral and systemic hemodynamics and gas exchange in very-low-birth-weight infants. J Pediatr 2004, 144:809-814.
18. Hudak M.L., Martin D.J., Egan E.A., et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997, 100:39-50.
19. Cummings J.J., Holm B.A., Hudak M.L., et al. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis 1992, 145:999-1004.
20. Horbar J.D., Wright L.L., Soll R.F., et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993, 123:757-766.
21. Sehgal S.S., Ewing C.K., Richards T., et al. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc 1994, 86:46-52.
22. Vermont-Oxford Neonatal Network A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996, 97:1-6.
23. Modanlou H.D., Beharry K., Padilla G., et al. Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol 1997, 17:455-460.
24. da Costa D.E., Pai M.G.K., Al Kusaiby S.M. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing county. Pediatr Pulmonol 1999, 27:312-317.
25. Moya F.R., Gadzinowski J., Bancalari E., et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005, 115:1018-1029.
26. Hudak M.L., Farrell E.E., Rosenberg A.A., et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996, 128:396-406.
27. Kukkonen A.K., Virtanen M., Jarvenpaa A.L., Pokela M.L., Ikonen S., Fellman V. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatr 2000, 89:556-561.
28. Ainsworth S.B., Beresford M.W., Milligan D.W., et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet 2000, 355:1387-1392.
29. Bloom B.T., Kattwinkel J., Hall R.T., et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997, 100:31-38.
30. Bloom B.T., Clark R.H. Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics 2005, 116:392-399.
31. Attar M.A., Becker M.A., Dechert R.E., Donn S.M. Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. J Perinatol 2004, 24:626-630.
32. Speer C.P., Gefeller O., Groneck P., et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1995, 72:F8-13.
33. Baroutis G., Kaleyias J., Liarou T., Papathoma E., Hatzistamatiou Z., Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr 2003, 162:476-480.
34. Ramanathan R., Rasmussen M.R., Gerstmann D.R., Finer N., Sekar K. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004, 21:109-119.
35. Malloy C.A., Nicoski P., Muraskas J.K. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005, 94:779-784.
36. Fujii A.M., Patel S.M., Allen R., Doros G., Guo C.-Y., Testa S. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J Perinatol 2010, 30:665-670.
37. Gharehbaghi M.M., Sakha S.H.P., Ghojazadeh M., Firoozi F. Complications among premature neonates treated with beractant and poractant alfa. Indian J Pediatr 2010, 77:751-754.
38. Sinha S.K., Lacaze-Masmonteil T., Soler A.V., et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005, 115:1030-1038.
39. Moya F., Sinha S., Gadzinowski J., et al. One-year follow up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter, randomized, controlled trials. Pediatrics 2007, 119:e1361-e1370.
40. Verder H., Albertsen P., Ebbesen F., et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 1999, 103:e24-e29.
41. Morley C.J., Davis P.G., Doyle L.W., et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008, 358:700-708.
42. SUPPORT Study Group of the Eunice Kennedy Schriver NICHD Neonatal Network Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010, 362:1970-1978.
43. Sandri F., Plavka R., Ancore G., et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics 2010, 125:e1402-e1409.
44. Kribs A., Hartel C., Kattner E., et al. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Padiatr 2010, 222:13-17.
45. Te Pas A.B., Walther F.J. A randomized, controlled trial of delivery-room respiratory management in very preterm infants. Pediatrics 2007, 120:322-329. Erratum in: Pediatrics 2007;120:936.
46. ® combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulmon Drug Deliv 2010, 23:303-309.
47. Chong E., Greenspan J., Kirkby S., Culhane J., Dysart K. Changing use of surfactant over 6 years and its relationship to chronic lung disease. Pediatrics 2008, 122:e927-e1021.
48. Tyson J.E., Wright L.L., Oh W., et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999, 340:1962-1968.
49. Schmidt B., Roberts R.S., Davis P., et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007, 357:1893-1902.